在患有类风湿性关节炎的患者中,奥索拉利祖马布的人口药理动力学
Tsutomu Takeuchi1,2, Yukihiro Chino3, Yoko Mano3
1Saitama Medical University, Saitama, Japan.
Journal of clinical pharmacology
|November 1, 2023
概括
双特异性NANOBODY的Ozoralizumab有效抑制瘤亡因子α (TNFα) 并在日本类风湿性关节炎患者中显示出可预测的药理动力学. 体重是影响其药物暴露的主要因素.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 奥索拉利祖马布是一种双特异性纳米体,向瘤亡因子α (TNFα) 和人血清白蛋白.
- 它抑制TNFα活性,并通过结合专蛋白提供长时间的血保留.
研究的目的:
- 在日本的类风湿性关节炎患者中开发奥索拉利祖马布 (ozoralizumab) 的人口药理动力学 (PK) 模型.
- 评估各种共同变量对奥索拉利祖马布的PK概况的影响.
主要方法:
- 使用来自494名日本患者的数据构建了一个人群PK模型.
- 该模型采用了1个隔间结构,具有第一阶段的吸收和消除.
- 共变量分析包括体重,性别,抗药抗体,eGFR和甲状腺素使用.
主要成果:
- 体重和性别被确定为明显清除和分布体积的共变量.
- 体重对奥索拉利祖马布PK的影响最为显著.
- 其他共同变量有轻微的影响,没有观察到临床相关的影响.
结论:
- 开发的人口PK模型准确地描述了日本类风湿性关节炎患者中ozoralizumab的行为.
- 尽管有轻微的共变效应,但该模型支持优化奥索拉利祖马布的剂量策略.
相关概念视频
Analysis of Population Pharmacokinetic Data
267
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
267
Quantitative Aspects of Drug-Receptor Interaction
1.0K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.0K
Drug Distribution: Plasma Protein Binding
5.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.7K
Antiepileptic Drugs: Potassium Channel Activators
191
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
191
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
42
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
42
Bioavailability: Overview
2.8K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
2.8K


